Kayne Anderson Rudnick Investment Management LLC Has $89.93 Million Stock Position in U.S. Physical Therapy, Inc. (NYSE:USPH)

Kayne Anderson Rudnick Investment Management LLC decreased its stake in shares of U.S. Physical Therapy, Inc. (NYSE:USPH - Free Report) by 9.3% in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,013,777 shares of the company's stock after selling 103,418 shares during the quarter. Kayne Anderson Rudnick Investment Management LLC owned approximately 6.71% of U.S. Physical Therapy worth $89,932,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in USPH. Vanguard Group Inc. increased its position in shares of U.S. Physical Therapy by 0.6% in the fourth quarter. Vanguard Group Inc. now owns 1,084,197 shares of the company's stock valued at $96,179,000 after buying an additional 6,393 shares in the last quarter. Copeland Capital Management LLC boosted its stake in shares of U.S. Physical Therapy by 9.5% during the 4th quarter. Copeland Capital Management LLC now owns 839,356 shares of the company's stock worth $74,459,000 after acquiring an additional 72,715 shares in the last quarter. Southernsun Asset Management LLC grew its stake in U.S. Physical Therapy by 4.5% in the 4th quarter. Southernsun Asset Management LLC now owns 571,809 shares of the company's stock valued at $50,725,000 after acquiring an additional 24,698 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of U.S. Physical Therapy by 1.9% during the 4th quarter. Dimensional Fund Advisors LP now owns 426,298 shares of the company's stock worth $37,818,000 after acquiring an additional 7,890 shares during the period. Finally, Envestnet Asset Management Inc. increased its holdings in shares of U.S. Physical Therapy by 20.1% during the 4th quarter. Envestnet Asset Management Inc. now owns 299,791 shares of the company's stock worth $26,594,000 after buying an additional 50,163 shares during the last quarter.

U.S. Physical Therapy Stock Down 0.5%

USPH stock traded down $0.36 during midday trading on Friday, hitting $75.24. The stock had a trading volume of 28,875 shares, compared to its average volume of 111,355. U.S. Physical Therapy, Inc. has a 52-week low of $62.77 and a 52-week high of $102.89. The business has a 50-day moving average of $71.99 and a two-hundred day moving average of $82.83. The company has a debt-to-equity ratio of 0.27, a current ratio of 1.78 and a quick ratio of 1.78. The firm has a market cap of $1.14 billion, a price-to-earnings ratio of 80.09, a price-to-earnings-growth ratio of 3.54 and a beta of 1.44.

U.S. Physical Therapy (NYSE:USPH - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.46 by $0.02. The firm had revenue of $183.79 million for the quarter, compared to analysts' expectations of $176.78 million. U.S. Physical Therapy had a net margin of 3.54% and a return on equity of 8.11%. The company's revenue for the quarter was up 18.0% compared to the same quarter last year. During the same quarter last year, the business posted $0.51 earnings per share. As a group, equities research analysts forecast that U.S. Physical Therapy, Inc. will post 2.67 earnings per share for the current fiscal year.

U.S. Physical Therapy Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, June 13th. Shareholders of record on Friday, May 23rd will be given a $0.45 dividend. The ex-dividend date is Friday, May 23rd. This represents a $1.80 dividend on an annualized basis and a yield of 2.39%. U.S. Physical Therapy's payout ratio is currently 82.57%.

Insiders Place Their Bets

In other U.S. Physical Therapy news, COO Graham D. Reeve sold 1,730 shares of U.S. Physical Therapy stock in a transaction dated Friday, March 7th. The shares were sold at an average price of $82.11, for a total transaction of $142,050.30. Following the completion of the transaction, the chief operating officer now owns 7,168 shares in the company, valued at approximately $588,564.48. The trade was a 19.44% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. 2.00% of the stock is currently owned by company insiders.

Analyst Upgrades and Downgrades

A number of equities analysts have issued reports on the stock. Wall Street Zen raised shares of U.S. Physical Therapy from a "sell" rating to a "hold" rating in a report on Thursday, May 8th. JMP Securities reissued a "market outperform" rating and issued a $113.00 price objective on shares of U.S. Physical Therapy in a research note on Tuesday, April 22nd. JPMorgan Chase & Co. reduced their target price on shares of U.S. Physical Therapy from $120.00 to $110.00 and set an "overweight" rating on the stock in a research note on Wednesday, March 19th. William Blair restated a "market perform" rating on shares of U.S. Physical Therapy in a research report on Thursday, February 27th. Finally, Barrington Research dropped their price objective on shares of U.S. Physical Therapy from $108.00 to $98.00 and set an "outperform" rating on the stock in a report on Friday, February 28th. Two investment analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $109.00.

U.S. Physical Therapy Profile

U.S. Physical Therapy, Inc operates outpatient physical therapy clinics. The company operates through Physical Therapy Operations and Industrial Injury Prevention Services segments. The company provides pre-and post-operative care and treatment for orthopedic-related disorders, sports-related injuries, preventative care, rehabilitation of injured workers, and neurological-related injuries.